Onesource Specialty Pharma: OneSource receives USFDA EIR with VAI Classification, Marking completion of Inspection process at its…
Onesource Specialty Pharma (ONESOURCE) filed a disclosure titled "OneSource receives USFDA EIR with VAI Classification, Marking completion of Inspection process at its Sterile Product Division (SPD) Facility in Bengaluru". The company is valued at about…
What happened
Onesource Specialty Pharma (ONESOURCE) filed a disclosure with the exchanges on 30 October 2026 at 02:07 PM titled "OneSource receives USFDA EIR with VAI Classification, Marking completion of Inspection process at its Sterile Product Division (SPD) Facility in Bengaluru".
Company snapshot
Onesource Specialty Pharma is a small-cap company in the Healthcare sector, with a market value of about ₹17,935 crore.
The stock last traded at ₹1,564, against a 52-week range of ₹1,057–₹1,925 (18.8% below the high).
Before this filing the shares had moved −1.6% over the month and −9.8% over three months. Average daily turnover over the last 20 sessions was about ₹120 crore.
Promoters held 30.47% at the end of Q2 FY27, down 0.01% points from the previous quarter; 38.80% of promoter shares were pledged. Foreign institutions owned 19.46% and domestic institutions 24.21%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q2 FY26 | 376 | 10.5 | 0.92 |
| Q3 FY26 | 290 | -88.7 | -7.74 |
| Q4 FY26 | 428 | 4.6 | 0.4 |
| Q1 FY27 | 449 | 25 | 2.18 |
| Q2 FY27 | 965 | 82.5 | 7.19 |
What history shows
This is not the company's first approval disclosure: BCEIE has 1 earlier filing of this kind on record since May 2026.
Across 122 similar disclosures by other Healthcare companies, shares moved +0.4% on average the next day and +1.1% over five days; 52% of them rose the next day.
Market-wide, 1,541 approval filings with an impact score of 50 or more saw an average next-day move of +0.1%, with 47% rising.
Past reactions describe what happened before; they are not a forecast.
In the news
Recent coverage elsewhere (links open the original publisher):
- Onesource Specialty Pharma Q2 Results: Stock jumps 8% on strong operating performance, revenue growth
- OneSource Specialty Pharma’s Q2 profit more than doubles on new capacity, volume growth
- OneSource Specialty Pharma Share Price Rises Over 8% On Results
- OneSource Specialty Pharma shares jump 14% after Q2 results; recover 50% from recent lows
- OneSource Specialty Pharma (NSEI:ONESOURCE) Stock Forecast & Analyst Predictions
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.